CL2011002690A1 - Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis. - Google Patents
Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.Info
- Publication number
- CL2011002690A1 CL2011002690A1 CL2011002690A CL2011002690A CL2011002690A1 CL 2011002690 A1 CL2011002690 A1 CL 2011002690A1 CL 2011002690 A CL2011002690 A CL 2011002690A CL 2011002690 A CL2011002690 A CL 2011002690A CL 2011002690 A1 CL2011002690 A1 CL 2011002690A1
- Authority
- CL
- Chile
- Prior art keywords
- teta
- pkc
- atherosclerosis
- pyrimidin
- diamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un método para tratar un trastorno inmunológico o la aterosclerosis que comprende tratar la sangre del paciente con un inhibidor de pkc-teta ex vivo y luego readministrar la sangre tratada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17323709P | 2009-04-28 | 2009-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002690A1 true CL2011002690A1 (es) | 2012-04-27 |
Family
ID=42332785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002690A CL2011002690A1 (es) | 2009-04-28 | 2011-10-27 | Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120196919A1 (es) |
EP (1) | EP2445503A1 (es) |
JP (1) | JP2012525403A (es) |
KR (1) | KR20120005460A (es) |
CN (1) | CN102421435A (es) |
AU (1) | AU2010241701A1 (es) |
BR (1) | BRPI1014775A2 (es) |
CA (1) | CA2760305A1 (es) |
CL (1) | CL2011002690A1 (es) |
EA (1) | EA201101568A1 (es) |
IL (1) | IL215939A0 (es) |
MX (1) | MX2011011290A (es) |
NZ (1) | NZ595331A (es) |
WO (1) | WO2010126967A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2187957A4 (en) | 2007-08-31 | 2011-08-24 | Univ Michigan | SELECTIVE CYTOPHERESIS DEVICES AND CORRESPONDING METHODS |
CN102459577B (zh) | 2009-05-18 | 2014-08-20 | 特拉科斯有限公司 | 适合临床应用于免疫介导性疾病的、具有增强型抑制功能的调节性t细胞的体外扩增方法 |
CA2803248A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
JP2013534249A (ja) | 2010-08-17 | 2013-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス科ウイルス感染の処置または予防のための化合物および方法 |
CN103260670A (zh) | 2010-10-15 | 2013-08-21 | 塞托弗尔克斯股份有限公司 | 细胞分离灌流器及其用途 |
WO2012174412A2 (en) * | 2011-06-16 | 2012-12-20 | La Jolla Institute For Allergy And Immunology | Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
AU2012286853A1 (en) | 2011-07-26 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
EP2766065A4 (en) | 2011-10-14 | 2016-06-15 | Cytopherx Inc | CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
WO2014124134A1 (en) | 2013-02-07 | 2014-08-14 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
RU2727520C2 (ru) | 2014-11-21 | 2020-07-22 | Ф2Г Лимитед | Противогрибковые агенты |
ES2962885T3 (es) | 2015-05-15 | 2024-03-21 | Massachusetts Gen Hospital | Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral |
WO2017041002A1 (en) * | 2015-09-04 | 2017-03-09 | Blazar Bruce R | Methods and compositions for increasing the suppressive function of regulatory t-cells (tregs) |
WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
WO2017197331A2 (en) | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1438053E (pt) * | 2001-10-17 | 2008-09-25 | Boehringer Ingelheim Int | Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação |
WO2004043386A2 (en) * | 2002-11-08 | 2004-05-27 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells and methods of their use |
JP2006515014A (ja) * | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体 |
US7601714B2 (en) * | 2004-07-08 | 2009-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
-
2010
- 2010-04-28 JP JP2012508629A patent/JP2012525403A/ja active Pending
- 2010-04-28 NZ NZ595331A patent/NZ595331A/xx not_active IP Right Cessation
- 2010-04-28 CN CN2010800185205A patent/CN102421435A/zh active Pending
- 2010-04-28 CA CA2760305A patent/CA2760305A1/en not_active Abandoned
- 2010-04-28 KR KR1020117023974A patent/KR20120005460A/ko not_active Application Discontinuation
- 2010-04-28 EA EA201101568A patent/EA201101568A1/ru unknown
- 2010-04-28 EP EP10717377A patent/EP2445503A1/en not_active Withdrawn
- 2010-04-28 WO PCT/US2010/032707 patent/WO2010126967A1/en active Application Filing
- 2010-04-28 MX MX2011011290A patent/MX2011011290A/es not_active Application Discontinuation
- 2010-04-28 AU AU2010241701A patent/AU2010241701A1/en not_active Abandoned
- 2010-04-28 BR BRPI1014775A patent/BRPI1014775A2/pt not_active IP Right Cessation
- 2010-04-28 US US13/266,757 patent/US20120196919A1/en not_active Abandoned
-
2011
- 2011-10-26 IL IL215939A patent/IL215939A0/en unknown
- 2011-10-27 CL CL2011002690A patent/CL2011002690A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102421435A (zh) | 2012-04-18 |
US20120196919A1 (en) | 2012-08-02 |
AU2010241701A1 (en) | 2011-10-13 |
IL215939A0 (en) | 2012-01-31 |
WO2010126967A1 (en) | 2010-11-04 |
NZ595331A (en) | 2013-08-30 |
JP2012525403A (ja) | 2012-10-22 |
MX2011011290A (es) | 2012-02-13 |
EP2445503A1 (en) | 2012-05-02 |
CA2760305A1 (en) | 2010-11-04 |
BRPI1014775A2 (pt) | 2016-04-19 |
EA201101568A1 (ru) | 2012-05-30 |
KR20120005460A (ko) | 2012-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002690A1 (es) | Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis. | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
CR20120173A (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
EP2575884A4 (en) | APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA | |
CO7160059A2 (es) | Formulación líquida | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
BR112014009993A2 (pt) | método para o tratamento de tumores do estroma gastrointestinal | |
MX2017013496A (es) | Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk). | |
EA201690745A1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" | |
CL2008002089A1 (es) | Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto. | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112015027477A2 (pt) | método para tratamento de um transtorno de deglutição | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" |